Prostate Cancer

Common Questions & Answers
More than 99 percent of people with prostate cancer that doesn’t spread from the original site of growth live for five years or longer compared to those who don’t have cancer, according to the American Cancer Society.
Warning signs of early prostate cancer include needing to urinate often (especially at night), weak, painful, or burning pee, and blood in the pee or semen. However, prostate cancer doesn’t always cause symptoms. Regular testing can rule it out.
This depends on the stage and type of cancer. Delaying treatment for lower-stage prostate cancer that has not spread may not increase the risk of death. Cancer that spreads from the prostate has risks affecting other organs.
Stages track prostate cancer’s spread and severity. Stage 1 and 2 cancers have stayed in the prostate, stage 3 means cancer has reached nearby structures, and stage 4 has spread to other organs near the prostate.

Walter Tsang, MD
Medical Reviewer
Outside of his busy clinical practice, Tsang has taught various courses at UCLA Center for East West Medicine, Loma Linda University, and California University of Science and Medicine. He is passionate about health education and started an online seminar program to teach cancer survivors about nutrition, exercise, stress management, sleep health, and complementary healing methods. Over the years, he has given many presentations on integrative oncology and lifestyle medicine at community events. In addition, he was the founding co-chair of a lifestyle medicine cancer interest group, which promoted integrative medicine education and collaborations among oncology professionals.
Tsang is an active member of American Society of Clinical Oncology, Society for Integrative Oncology, and American College of Lifestyle Medicine. He currently practices at several locations in Southern California. His goal is to transform cancer care in the community, making it more integrative, person-centered, cost-effective and sustainable for the future.

Christopher Wolter, MD
Medical Reviewer
Christopher Wolter, MD, is an assistant professor in urology at Mayo Clinic in Phoenix, Arizona. He has been in practice since 2008, specializing in the areas of urinary incontinence, pelvic organ prolapse, urologic reconstruction, urologic prosthetics, post prostate cancer survivorship, erectile dysfunction, neurourology and neuromodulation, and overall functional considerations of urogenital health.
Dr. Wolter has been heavily involved in urologic education. He spent the last 12 years heavily involved in resident education and leadership for his department, including the last eight years as urology residency program director. He currently serves as the director of urologic education for the preclinical and clinical rotations for the Mayo Clinic Alix School of Medicine Phoenix, Arizona, campus.
Wolter completed his undergraduate and medical education at the University of Illinois. He then completed his urology residency at Tulane University in New Orleans, followed by a fellowship in female pelvic medicine and reconstructive urology at Vanderbilt University in Nashville, Tennessee.

Thomas Urban Marron, MD, PhD
Medical Reviewer
Dr. Marron received his bachelor's degree in human biology from the University of Virginia in Charlottesville in 2005, his PhD in immunology from the Icahn School of Medicine in 2010, and his MD from the Icahn School of Medicine in 2012. He remained at Mount Sinai Hospital for his internal medicine residency, which he completed in 2014, and for his clinical fellowships in hematology and medical oncology, which he completed in 2017.

Conor Steuer, MD
Medical Reviewer
Conor E. Steuer, MD, is medical oncologist specializing in the care of aerodigestive cancers, mesothelioma, and thymic malignancies and an assistant professor in the department of hematology and medical oncology at the Emory University School of Medicine in Atlanta. He joined the clinical staff at Emory's Winship Cancer Institute as a practicing physician in July 2015. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group and is a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Dr. Steuer received his medical degree from the New York University School of Medicine in 2009. He completed his postdoctoral training as a fellow in the department of hematology and medical oncology at the Emory University School of Medicine, where he was chief fellow in his final year.
He has been active in research including in clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.
Steuer's work has been published in many leading journals, such as Cancer, the Journal of Thoracic Oncology, and Lung Cancer, and has been presented at multiple international conferences.

Daniel Landau, MD
Medical Reviewer
Daniel Landau, MD, is a distinguished board-certified hematologist-oncologist with a career that has spanned two eminent institutions: the Orlando Health Cancer Institute and the Medical University of South Carolina. With a specialized interest in genitourinary oncology and hematology, he has been at the forefront of managing both benign and malignant conditions.
Dr. Landau is a pioneering figure in integrating advanced technology into oncology, having served as a director of telemedicine services. Under his leadership, multiple innovative systems have been designed and piloted, all with a singular focus: enhancing the patient experience.
Beyond his clinical and technological endeavors, Landau is deeply committed to medical education. He has dedicated significant time and expertise to nurturing the skills of medical students, residents, and fellows, ensuring that the flame of knowledge and compassion burns bright in the next generation of oncologists.

Ryland J. Gore, MD, MPH
Medical Reviewer
In addition to her professional responsibilities, Gore previously served on the board of directors for Every Woman Works, an Atlanta-based nonprofit organization whose mission is to empower women and help them transition into independence and stability from common setbacks. Gore served as the chairwoman of the American Cancer Society’s Making Strides Against Breast Cancer campaign in Atlanta for three years (2019 to 2021). She is currently the co-director of Nth Dimensions’ Strategic Mentoring Program and the alumni board chair of the Summer Health Professions Educational Program (SHPEP), which is a collaborative effort by the Robert Wood Johnson Foundation, Association of American Medical Colleges, and the American Dental Education Association.
Gore is a highly sought after speaker, consultant, and lecturer on breast cancer and breast health, as well as women’s empowerment topics.
- Prostate Cancer Treatment (PDQ®) — Patient Version. National Cancer Institute. December 20, 2024.
ALL PROSTATE CANCER ARTICLES









